Combination Targeted Therapy

• 6483 · PDF CDK4/6与PI3K/mTOR通路的趋同性过度激活在RB1功能完好和RB1缺陷背景下均定义了骨肉瘤中一个可靶向的轴 Convergent CDK4/6 and PI3K/mTOR pathway hyperactivation defines a targetable axis in osteosarcoma across RB1-proficient and RB1-deficient contexts Lauren K. Stevens, M. Reza Saadatzadeh, Farinaz Barghi, Erika A. Dobrota, Harlan E. Shannon, Rada Malko, Ryli Justice, Christopher Davis, Keiko Kreklau, Melissa A. Trowbridge, Kathy Coy, Felicia M. Kennedy, Anthony L. Sinn, Kyle W. Jackson, George Sandusky, L. Daniel Wurtz, Christopher D. Collier, Dana Mitchell, Ed Greenfield, Emma H. Doud, Amber L. Mosley, Steven P. Angus, Pankita H. Pandya, Karen E. Pollok
• 6484 · PDF SPOP和CHD1在ACSL4调控中的分歧作用揭示了前列腺癌中靶向铁死亡的情境依赖性易感性 Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis in prostate cancer Feiyu Chen, Qidong Li, Qianlin Gu, Javier Leo, Xin Liang, Naayaa Mehta, Yin Wang, Francisco R. Saenz, Maya M. Phillips, Wei Shi, Chenling Meng, Jie Zhang, Boyi Gan, Di Zhao
• 6485 · PDF GCN2激活剂HC-7366与VEGFR-TKI联用在ccRCC中的疗效优于单用VEGFR-TKI或VEGFR-TKI/HIF-2i联合 Combination of the GCN2 activator HC-7366 with VEGFR-TKI results in greater efficacy than VEGFR-TKI alone or VEGFR-TKI/HIF-2i combinations in ccRCC Weiyu Zhang, Kathryn Bieging-Rolett, Ashley LaCayo, Ben Harrison, Jeremy Drees, Crissy Dudgeon, Nandita Bose, Eric S. Lightcap
• 6487 · PDF 卡瑞利珠单抗联合化疗作为晚期食管鳞状细胞癌二线治疗的探索性研究 Exploratory study of camrelizumab combined with chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma Linlin Wang, Bingjie Fan, Bing Zou, Aiqin Gao, Shijiang Wang, Chunni Wang, Qian Shao, Yishan Yu, Hong Zhao, Jinzhi Wang, Yan Yi, Qingxi Yu
• 6488 · PDF 双重靶向PARP和RAS增强胰腺癌的抗肿瘤活性 Dual targeting of PARP and RAS enhances antitumor activity in pancreatic cancer Chani Stossel, Gali Altman, Dikla Atias, Yulia Glick Gorman, Hanita Ovadia, Liora Chouchan, Elina Haimov-Talmoud, Maria Raitses-Gurevich, Tamar Beller, Talia Golan
• 6489 · PDF 卵巢癌的代谢分子分型揭示油酸-CD36在促进顺铂耐药中的作用 Metabolic molecular subtyping of ovarian cancer reveals the role of oleic acid-CD36 in facilitating cisplatin resistance Jiagui Song
• 6490 · PDF MEK抑制在AML共培养和血管化间充质类器官中克服基质介导的对MERTK靶向治疗的耐药 MEK inhibition overcomes stromal-mediated resistance to a MERTK targeted therapy in AML co-cultures and vascularized mesenchymal organoids Chloe Hope, Katherine Minson, Eleana Vasileiadi, Madeline G. Higgins, Alejandro De Janon, Shuichi Takayama, Xiaodong Wang, Steven Frye, H. Shelton Earp, Douglas K. Graham, Deborah DeRykere
• 6491 · PDF FAK抑制剂与PARP抑制剂联合治疗同源重组功能正常的高级别浆液性卵巢癌 Co-treatment with FAK and PARP inhibitors for the treatment of homologous recombination-proficient high grade serious ovarian cancer Caree Carson, Breana Hill, Aarya Ghosalkar, Marjaana Ojalill, Antonia Boyer, Xiao Lei Chen, David Schlaepfer, Dwayne Stupack
• 6492 · PDF 靶向磷脂酶D1可克服铂类耐药并增强顺铂在卵巢癌中的疗效 Targeting phospholipase D1 overcomes platinum resistance and enhances cisplatin efficacy in ovarian cancer Shin-Wha Lee, Sung Wan Kang, Dong Woo Kang, Yu-na Noh, Young-Jae Lee, Min-Seo Lee, Yong-Man Kim
• 6493 · PDF Azvudine联合Doxitinib——EGFRm+ NSCLC的潜在疗法 Azvudine combined with Doxitinib, a potential therapy for EGFRm + NSCLC Jianmei Zhang, Shufang Zhang, Yujie Wang, Limin Jia, Ying Li, Pan Li, Feng Luo, Jinfa Du
• 6494 · PDF 选择性YAP/TEAD抑制剂TY-1054增强KRAS抑制剂或Trop2-ADC在多种实体瘤中的疗效 The selective YAP/TEAD inhibitor TY-1054 enhances the efficacy of KRAS inhibitors or Trop2-ADC in multiple solid tumors Shengli Dong, Zhengfei Guo, Zhiyong He, Apeng Liang, Meihua Li, Guangbin Liu, Chao Zhou, Yu Yu, Xinlong Yang, Hongqiang Li, Chengshan Niu, Shaoqing Chen, Jun Li, Yusheng Wu
• 6495 · PDF NXP900——一种处于1b期、同类首创的YES1/SRC抑制剂，在KRASi敏感和耐药的NSCLC模型中显示出与KRAS抑制剂的强效协同作用 NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models Boback Kaghazchi, Enrique Podarosu, Asier Unciti-Broceta, Neil O. Carragher
• 6496 · PDF 甲基硒酸增强抗FN14 CAR-T细胞的效应功能，并将细胞毒性重新导向富含TGF-beta的肾脏、前列腺和脑肿瘤 Methylseleninic acid enhances anti-FN14 CAR-T cell effector function and redirects cytotoxicity against TGF-beta-rich kidney, prostate, and brain tumors Gloria B. Kim, Obed B. Amissah, Casey R. Ager, Yousef Zakharia, Youcef M. Rustum
• 6497 · PDF 协同破坏KRAS和FAK通路：一条用于优化PDAC治疗的临床前研发管线 Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimization Jaeger Moore, Taylor Bargenquast, Tithi Ghosh Halder, Serina Ng, Erkut Borazanci, Sara A. Byron, Cherie Wesley, Raffaella Soldi, Sunil Sharma
• 6498 · PDF MDM2抑制剂与亲脂性吉西他滨的联合：在肺癌中呈强协同作用，而在脑癌中呈拮抗作用 Combination of MDM2 inhibitor and lipophilic gemcitabine: Strong synergism in lung cancer, while antagonism in brain cancer Bhoomi Mukeshbhai Dholariya, Akanksha S. Patel, Ketankumar Patel
• 6499 · PDF 靶向慢性髓系白血病中不依赖BCR-ABL1的耐药机制 Targeting BCR-ABL1-independent mechanisms of resistance in chronic myeloid leukemia Mark Pusung, Christopher A. Eide, Jessica Gibbs, Daniel Bottomly, Haijiao Zhang, Brian J. Druker
• 6501 · PDF 阿来替尼与依维莫司在ALK阳性非小细胞肺癌中协同活性的临床前证据 Preclinical evidence for synergistic activity of alectinib and everolimus in ALK-positive non-small cell lung cancer Hamadi Madhi, Habib Serhan, Rachel Mercer, Benjamin Levy, Anna Rottinghaus, Liwei Bao, Xu Cheng, Sharon R. Pine, Ross Camidge, Angel Qin, Nathan M. Merrill, Sofia D. Merajver, Matthew B. Soellner
• 6503 · PDF 研究CK2与C-KIT抑制在B-ALL中的协同效应 Investigating synergistic effects with CK2 and C-KIT inhibition in B-ALL Daniel Bogush, Stephanie Buczkowski, Rabab Husain, Sameer Ahmed Bhat, Yen Teng Tai, Avinash Kundadka Kudva, Sinisa Dovat
• 6505 · PDF 选择性SMARCA2（BRM）抑制剂HD-11273联合治疗用于治疗SMARCA4（BRG1）缺陷型癌症 Combination therapy with selective SMARCA2 (BRM) inhibitor HD-11273 for treatment of SMARCA4 (BRG1)-deficient cancers Hyuntae Kim, MinOu Choi, Jongwoo Park, Goeun Yang, Min-Ah Park, Hyo Sun Choi, Yukyung Kim, Doo-Young Kim, Daehoon Kim, Seong Heon Kim, Suk Ho Lee
• 6506 · PDF AOH1996及下一代caPCNA抑制剂与靶向及化疗药物联合的抗肿瘤协同作用 Antitumor synergy of AOH1996 and next-generation caPCNA Inhibitors in combination with targeted and chemotherapeutic agents Robert G. Lingeman, Long Gu, Caroline Li, Pouya Haratipour, Robert J. Hickey, Linda H. Malkas, Maryam Zangi
• 6507 6507 肺癌的基因组表征：ERRFI1和NKX2-1突变及CLU表达 Genomic characterization of lung cancer: ERRFI1 and NKX2-1 mutations and CLU expression Metamia Ciampricotti, Yingying Yu, Stamatina Fragkogianni, Jyoti Patel, Christine M. Lovly

在会议检索中浏览本分会场